Eagle Health Investments LP Boosts Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Eagle Health Investments LP lifted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,816 shares of the company’s stock after buying an additional 9,516 shares during the quarter. Kymera Therapeutics comprises 2.1% of Eagle Health Investments LP’s investment portfolio, making the stock its 17th biggest position. Eagle Health Investments LP’s holdings in Kymera Therapeutics were worth $12,145,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its holdings in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, State Street Corp lifted its holdings in Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares in the last quarter.

Kymera Therapeutics Trading Down 0.5%

KYMR stock opened at $110.05 on Tuesday. The company’s 50 day moving average is $96.85 and its 200 day moving average is $86.91. The stock has a market cap of $9.05 billion, a price-to-earnings ratio of -30.83 and a beta of 1.95. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period last year, the firm posted ($0.82) earnings per share. Kymera Therapeutics’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of Kymera Therapeutics stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,637,813 shares of company stock worth $390,253,404. Corporate insiders own 15.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on KYMR. Canaccord Genuity Group raised their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a report on Monday, June 8th. BTIG Research restated a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Bank of America boosted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Mizuho upped their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Twenty investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $122.64.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.